Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Lineage Commitment01:21

Lineage Commitment

Commitment is the  process whereby stem cells:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party.

The Lancet. Haematology·2026
Same author

Corrigendum to "A meta-analysis of criterion effects for the Implicit Relational Assessment Procedure (IRAP) in the clinical domain" [Journal of Behavior Therapy and Experimental psychiatry 48 (2015) 59-65].

Journal of behavior therapy and experimental psychiatry·2026
Same author

A Virtual Versus In-Person Comparison of the Senior Fitness Test: A Randomized Crossover Trial.

Physiotherapy Canada. Physiotherapie Canada·2026
Same author

Reduced-intensity reinduction for children and young persons with relapsed acute lymphoblastic leukemia.

Leukemia·2026
Same author

Long-term outcome of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia - a study on behalf of the Chronic Malignancies Working Party of the EBMT.

Haematologica·2026
Same author

Sweet's syndrome in acute myeloid leukaemia.

British journal of haematology·2026
Same journal

The next generation of therapies for chronic myeloid leukemia.

Clinical lymphoma & myeloma·2009
Same journal

Molecular monitoring of patients with chronic myeloid leukemia: clinical examples from a non-trial setting.

Clinical lymphoma & myeloma·2009
Same journal

Standard management of patients with chronic myeloid leukemia.

Clinical lymphoma & myeloma·2009
Same journal

Chronic myeloid leukemia: where do we go now?

Clinical lymphoma & myeloma·2009
Same journal

Bing-Neel syndrome: a case report and systematic review of clinical manifestations, diagnosis, and treatment options.

Clinical lymphoma & myeloma·2009
Same journal

Behçet's disease in a patient with myelodysplastic syndrome.

Clinical lymphoma & myeloma·2009
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

The chronic myeloid leukemia stem cell.

Emma Nicholson1, Tessa Holyoake

  • 1The Beatson West of Scotland Cancer Centre, Glasgow, UK. emma.nicholson@nhs.net

Clinical Lymphoma & Myeloma
|December 17, 2009
PubMed
Summary
This summary is machine-generated.

Chronic myeloid leukemia (CML) originates from leukemic stem cells (LSC) with self-renewal properties. These LSC can be resistant to treatments like imatinib, potentially causing disease relapse.

More Related Videos

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
05:24

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Related Experiment Videos

Last Updated: Jun 17, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
05:24

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Area of Science:

  • Hematology
  • Cancer Biology
  • Stem Cell Research

Background:

  • Chronic myeloid leukemia (CML) is a stem cell disorder driven by the BCR-ABL translocation.
  • Leukemic stem cells (LSC) possess self-renewal and differentiation capabilities, similar to normal hematopoietic stem cells (HSC).
  • LSC can cause leukemia upon transplantation, and a subset remains quiescent, exhibiting resistance to growth factors.

Purpose of the Study:

  • To investigate the characteristics of CML stem cells, particularly their role in disease persistence and treatment resistance.
  • To understand the mechanisms underlying LSC self-renewal and quiescence in CML.
  • To explore the implications of LSC properties for CML progression and relapse.

Main Methods:

  • Isolation and characterization of LSC from CML patients.
  • Transplantation of LSC into NOD-SCID mouse models to assess leukemogenic potential.
  • In vitro studies to evaluate the response of quiescent CML stem cells to imatinib treatment.

Main Results:

  • LSC were isolated and confirmed to cause leukemia in vivo.
  • A fraction of CML stem cells were found to be quiescent and resistant to imatinib.
  • This resistance contributes to disease persistence and potential relapse after initial treatment response.

Conclusions:

  • CML stem cells, especially quiescent ones, are key drivers of disease persistence and relapse due to inherent drug resistance.
  • Understanding LSC properties is crucial for developing effective therapies targeting the stem cell pool.
  • Newer therapies aim to specifically eradicate CML stem cells to achieve durable remission.